共查询到20条相似文献,搜索用时 0 毫秒
1.
Tracy M. Crotty Tomoyuki Nakano Diana M. Stafforini Matthew K. Topham 《The Journal of biological chemistry》2013,288(3):1439-1447
Discovering proteins that modulate Akt signaling has become a critical task, given the oncogenic role of Akt in a wide variety of cancers. We have discovered a novel diacylglycerol signaling pathway that promotes dephosphorylation of Akt. This pathway is regulated by diacylglycerol kinase δ (DGKδ). In DGKδ-deficient cells, we found reduced Akt phosphorylation downstream of three receptor tyrosine kinases. Phosphorylation upstream of Akt was not affected. Our data indicate that PKCα, which is excessively active in DGKδ-deficient cells, promotes dephosphorylation of Akt through pleckstrin homology domain leucine-rich repeats protein phosphatase (PHLPP) 2. Depletion of either PKCα or PHLPP2 rescued Akt phosphorylation in DGKδ-deficient cells. In contrast, depletion of PHLPP1, another Akt phosphatase, failed to rescue Akt phosphorylation. Other PHLPP substrates were not affected by DGKδ deficiency, suggesting mechanisms allowing specific modulation of Akt dephosphorylation. We found that β-arrestin 1 acted as a scaffold for PHLPP2 and Akt1, providing a mechanism for specificity. Because of its ability to reduce Akt phosphorylation, we tested whether depletion of DGKδ could attenuate tumorigenic properties of cultured cells and found that DGKδ deficiency reduced cell proliferation and migration and enhanced apoptosis. We have, thus, discovered a novel pathway in which diacylglycerol signaling negatively regulates Akt activity. Our collective data indicate that DGKδ is a pertinent cancer target, and our studies could lay the groundwork for development of novel cancer therapeutics. 相似文献
2.
3.
Bernard M. H. Law Victoria A. Spain Veronica H. L. Leinster Ruth Chia Alexandra Beilina Hyun J. Cho Jean-Marc Taymans Mary K. Urban Rosa M. Sancho Marian Blanca Ramírez Saskia Biskup Veerle Baekelandt Huaibin Cai Mark R. Cookson Daniel C. Berwick Kirsten Harvey 《The Journal of biological chemistry》2014,289(2):895-908
Mutations in LRRK2, encoding the multifunctional protein leucine-rich repeat kinase 2 (LRRK2), are a common cause of Parkinson disease. LRRK2 has been suggested to influence the cytoskeleton as LRRK2 mutants reduce neurite outgrowth and cause an accumulation of hyperphosphorylated Tau. This might cause alterations in the dynamic instability of microtubules suggested to contribute to the pathogenesis of Parkinson disease. Here, we describe a direct interaction between LRRK2 and β-tubulin. This interaction is conferred by the LRRK2 Roc domain and is disrupted by the familial R1441G mutation and artificial Roc domain mutations that mimic autophosphorylation. LRRK2 selectively interacts with three β-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4). Binding specificity is determined by lysine 362 and alanine 364 of β-tubulin. Molecular modeling was used to map the interaction surface to the luminal face of microtubule protofibrils in close proximity to the lysine 40 acetylation site in α-tubulin. This location is predicted to be poorly accessible within mature stabilized microtubules, but exposed in dynamic microtubule populations. Consistent with this finding, endogenous LRRK2 displays a preferential localization to dynamic microtubules within growth cones, rather than adjacent axonal microtubule bundles. This interaction is functionally relevant to microtubule dynamics, as mouse embryonic fibroblasts derived from LRRK2 knock-out mice display increased microtubule acetylation. Taken together, our data shed light on the nature of the LRRK2-tubulin interaction, and indicate that alterations in microtubule stability caused by changes in LRRK2 might contribute to the pathogenesis of Parkinson disease. 相似文献
4.
Jonathan K. Williams Xue Yang Tamr B. Atieh Michael P. Olson Sagar D. Khare Jean Baum 《Journal of molecular biology》2018,430(16):2360-2371
The intrinsically disordered protein β-synuclein is known to inhibit the aggregation of its intrinsically disordered homolog, α-synuclein, which is implicated in Parkinson's disease. While β-synuclein itself does not form fibrils at the cytoplasmic pH?7.4, alteration of pH and other environmental perturbations are known to induce its fibrilization. However, the sequence and structural determinants of β-synuclein inhibition and self-aggregation are not well understood. We have utilized a series of domain-swapped chimeras of α-synuclein and β-synuclein to probe the relative contributions of the N-terminal, C-terminal, and the central non-amyloid-β component domains to the inhibition of α-synuclein aggregation. Changes in the rates of α-synuclein fibril formation in the presence of the chimeras indicate that the non-amyloid-β component domain is the primary determinant of self-association leading to fibril formation, while the N- and C-terminal domains play critical roles in the fibril inhibition process. Our data provide evidence that all three domains of β-synuclein together contribute to providing effective inhibition, and support a model of transient, multi-pronged interactions between IDP chains in both processes. Inclusion of such multi-site inhibitory interactions spread over the length of synuclein chains may be critical for the development of therapeutics that are designed to mimic the inhibitory effects of β-synuclein. 相似文献
5.
Andrea Meixner Karsten Boldt Marleen Van Troys Manor Askenazi Christian J. Gloeckner Matthias Bauer Jarrod A. Marto Christophe Ampe Norbert Kinkl Marius Ueffing 《Molecular & cellular proteomics : MCP》2011,10(1):M110.001172
Mutations in human leucine-rich repeat kinase 2 (Lrrk2), a protein of yet unknown function, are linked to Parkinson''s disease caused by degeneration of midbrain dopaminergic neurons. The protein comprises several domains including a GTPase and a kinase domain both affected by several pathogenic mutations. To elucidate the molecular interaction network of endogenous Lrrk2 under stoichiometric constraints, we applied QUICK (quantitative immunoprecipitation combined with knockdown) in NIH3T3 cells. The identified interactome reveals actin isoforms as well as actin-associated proteins involved in actin filament assembly, organization, rearrangement, and maintenance, suggesting that the biological function of Lrrk2 is linked to cytoskeletal dynamics. In fact, we demonstrate Lrrk2 de novo binding to F-actin and its ability to modulate its assembly in vitro. When tested in intact cells, knockdown of Lrrk2 causes morphological alterations in NIH3T3 cells. In developing dopaminergic midbrain primary neurons, Lrrk2 knockdown results in shortened neurite processes, indicating a physiological role of Lrrk2 in cytoskeletal organization and dynamics of dopaminergic neurons. Hence, our results demonstrate that molecular interactions as well as the physiological function of Lrrk2 are closely related to the organization of the actin-based cytoskeleton, a crucial feature of neuronal development and neuron function.Parkinson''s disease (PD)1 is the second most prevalent neurodegenerative disorder but the underlying pathogenesis still remains elusive. The human leucine-rich repeat kinase 2 (Lrrk2, OMIM 609007) gene has been identified as the most common causative gene of autosomal-dominant inherited and idiopathic PD (1). To date, more than 50 variants within the Lrrk2 locus have been described, seven of which are confirmed to be pathogenic (2). The clinical symptoms of Lrrk2 mutation carriers are indistinguishable from those of idiopathic PD patients, whereas the related neuropathology is pleomorphic, including α-synucleinopathy, tauopathy, and ubiquitin deposits or nigral neuronal loss solely (3, 4). Therefore, Lrrk2 might be central to neurodegenerative pathways associated with parkinsonism (5). The expression pattern of Lrrk2 comprises many regions of the central nervous system as well as some peripheral organs like heart, liver, lung, and kidney (4, 6). The protein localizes to various neuronal populations of the brain, primarily striatum, cortex, and hippocampus (7, 8) as well as to the dopaminergic (DA) neurons of the substantia nigra pars compacta (9, 10).Lrrk2 encodes a large multidomain protein (∼286 kDa) belonging to the ROCO protein superfamily (4), comprising a characteristic combination of a ROC (Ras of complex protein) domain adjacent to a COR (C-terminal of ROC) domain (11), immediately followed by a kinase domain (mitogen-activated protein kinase kinase kinase). This catalytic region is flanked by other regulatory and protein-interaction domains (12). Although the domain structure of Lrrk2 is well known, the understanding of the physiological function and the impact of pathogenic mutations on the molecular mechanisms leading to PD still remain uncertain. In vitro studies demonstrated that Lrrk2 is both a functional kinase and GTPase, able to undergo autophosphorylation and perform phosphorylation of generic and putative physiological substrates (13–15). Some mutations have been shown to increase the protein''s kinase activity (16–18) and to induce cellular toxicity in vitro, leading to the hypothesis that the kinase activity contributes to neurodegeneration (18, 19). However, divergent reports on the enzymatic activity of mutant Lrrk2 (20) and the distribution of point mutations throughout the sequence of Lrrk2 indicate that not just the kinase domain is crucial for the physiological function. It is rather likely that intra- and intermolecular protein-protein interactions (PPIs) inside as well as outside of the kinase domain are essential for the normal function. Hence, alterations in the PPIs may underlie the pathomechanisms by which mutant Lrrk2 causes parkinsonism (21). A key step in understanding the physiological function of Lrrk2 and associated PD pathology is placing Lrrk2 into biochemical pathways by the identification of its protein interaction partners.Therefore, we systematically analyzed the Lrrk2 interactome using the QUICK (quantitative immunoprecipitation combined with knockdown) assay reported by Selbach and Mann (22). This approach assesses interactions between proteins at their endogenous levels and in their normal cellular environment by a combination of stable isotope labeling with amino acids in cell culture (SILAC) (23), RNA interference (RNAi), coimmunoprecipitation (co-IP), and quantitative mass-spectrometry (MS). By applying this screen in the murine NIH3T3 cell line we identified 36 proteins as robust Lrrk2 interactors whose majority are members of the actin family, actin-regulatory proteins, myosins, and proteins modulating their activity. To our knowledge, this is the first study reporting Lrrk2 protein interactions of the endogenous protein at its physiological expression level. We can show, that Lrrk2 cosediments with filamentous (F)-actin and affects the amount of F-actin in vitro, implying—in conjunction with the identified putative interactors—a function of Lrrk2 in the regulation of the actin cytoskeleton arrangement and/or dynamics. Significant morphological alterations of NIH3T3 cells upon lentiviral-mediated Lrrk2 knockdown raise further evidence for this hypothesis. Moreover, shRNA-based knockdown of Lrrk2 in primary ventral mesencephalic (VM) cells leads to impaired neurite outgrowth in developing DA neurons. These results indicate a functional association of Lrrk2 with the actin-based cytoskeleton, and suggest a role in regulating cellular morphology and structural plasticity. 相似文献
6.
Ayako Yoshida Takeo Tomita Tomohisa Kuzuyama Makoto Nishiyama 《The Journal of biological chemistry》2010,285(35):27477-27486
Aspartate kinase (AK) is the first and committed enzyme of the biosynthetic pathway producing aspartate family amino acids, lysine, threonine, and methionine. AK from Corynebacterium glutamicum (CgAK), a bacterium used for industrial fermentation of amino acids, including glutamate and lysine, is inhibited by lysine and threonine in a concerted manner. To elucidate the mechanism of this unique regulation in CgAK, we determined the crystal structures in several forms: an inhibitory form complexed with both lysine and threonine, an active form complexed with only threonine, and a feedback inhibition-resistant mutant (S301F) complexed with both lysine and threonine. CgAK has a characteristic α2β2-type heterotetrameric structure made up of two α subunits and two β subunits. Comparison of the crystal structures between inhibitory and active forms revealed that binding inhibitors causes a conformational change to a closed inhibitory form, and the interaction between the catalytic domain in the α subunit and β subunit (regulatory subunit) is a key event for stabilizing the inhibitory form. This study shows not only the first crystal structures of α2β2-type AK but also the mechanism of concerted inhibition in CgAK. 相似文献
7.
α-Synuclein plays a key role in the pathological neurodegeneration in Parkinson’s disease. Although its contribution to normal
physiology remains elusive, the selective degeneration of α-synuclein-containing dopaminergic neurons in Parkinson’s disease
may be linked to abnormal α-synuclein induced toxicity. In the present study, a complex of α-synuclein and vesicular monoamine
transporter-2 was identified by GST-Pull Down experiment. In wild-type α-synuclein stably transfected SH-SY5Y cell lines,
the activity of vesicular monoamine transporter-2 decreased by 31% as determined by [3H] dopamine uptake, and its expression also decreased in both protein and mRNA levels using western and northern blot analysis.
Overexpression of wild-type α-synuclein did not induce cell death or apoptosis, but significantly enhanced the intracellular
reactive oxygen species level as assayed by flow cytometry. These data suggest that Up-regulated α-synuclein expression inhibits
the activity of vesicular monoamine transporter-2, thereby interrupting dopamine homeostasis and resulting in dopaminergic
neuron injury in Parkinson’s disease. 相似文献
8.
α-Synuclein (αSYN) is genetically and neuropathologically linked to a spectrum of neurodegenerative diseases including Parkinson’s disease, dementia with Lewy bodies, and related disorders. Cognitive impairment is recapitulated in several αSYN transgenic mouse lines. However, the mechanisms of dysfunction in affected neurons are largely unknown. Here we measured neuronal activity induced gene products in the limbic system of αSYN transgenic mice upon fear conditioning (FC). Induction of the synaptic plasticity marker c-Fos was significantly reduced in the amygdala and hippocampus of (Thy1)-h[A30P]αSYN transgenic mice in an age-dependent manner. Similarly, the neuronal activity inducible polo-like kinase 2 (Plk2) that can phosphorylate αSYN at the pathological site serine-129 was up-regulated in both brain regions upon FC. Plk2 inductions were also significantly impaired in aged (Thy1)-h[A30P]αSYN transgenic mice, both in the amygdala and hippocampus. Plk2 inductions in the amygdala after FC were paralleled by a small but significant increase in the number of neuronal cell bodies immunopositive for serine-129 phosphorylated αSYN in young but not aged (Thy1)-h[A30P]αSYN transgenic mice. In addition, we observed in the aged hippocampus a distinct type of apparently unmodified transgenic αSYN profiles resembling synaptic accumulations of αSYN. Thus, the cognitive decline observed in aged αSYN transgenic mice might be due to impairment of neurotransmission and synaptic plasticity in the limbic system by distinct αSYN species. 相似文献
9.
M. Prescott A. G. McLennan D. C. Agathocleous P. C. Bulman Page R. Cosstick I. J. Galpin 《Nucleosides, nucleotides & nucleic acids》2013,32(2):297-303
Abstract Members of a series of α,ω-di(adenosin- N 6-yl)alkanes, comprising two adenosine residues linked with alkyl bridges from 1 to 14 methylene units in length, were found to be inhibitors of rat liver and BHK cell adenosine kinase. The inhibition was competitive with respect to adenosine and non-competitive with respect to ATP. The corresponding α,ω-di(cytidin-N 4-yl) alkanes were not inhibitors and N 6-alkyladenosines inhibited only weakly. 相似文献
10.
Background
The mechanisms through which aberrant α-synuclein (ASYN) leads to neuronal death in Parkinson''s disease (PD) are uncertain. In isolated liver lysosomes, mutant ASYNs impair Chaperone Mediated Autophagy (CMA), a targeted lysosomal degradation pathway; however, whether this occurs in a cellular context, and whether it mediates ASYN toxicity, is unknown. We have investigated presently the effects of WT or mutant ASYN on the lysosomal pathways of CMA and macroautophagy in neuronal cells and assessed their impact on ASYN-mediated toxicity.Methods and Findings
Novel inducible SH-SY5Y and PC12 cell lines expressing human WT and A53T ASYN, as well as two mutant forms that lack the CMA-targeting motif were generated. Such forms were also expressed in primary cortical neurons, using adenoviral transduction. In each case, effects on long-lived protein degradation, LC3 II levels (as a macroautophagy index), and cell death and survival were assessed. In both PC12 and SH-SY5Y cycling cells, induction of A53T ASYN evoked a significant decrease in lysosomal degradation, largely due to CMA impairment. In neuronally differentiated SH-SH5Y cells, both WT and A53T ASYN induction resulted in gradual toxicity, which was partly dependent on CMA impairment and compensatory macroautophagy induction. In primary neurons both WT and A53T ASYN were toxic, but only in the case of A53T ASYN did CMA dysfunction and compensatory macroautophagy induction occur and participate in death.Conclusions
Expression of mutant A53T, and, in some cases, WT ASYN in neuronal cells leads to CMA dysfunction, and this in turn leads to compensatory induction of macroautophagy. Inhibition of these lysosomal effects mitigates ASYN toxicity. Therefore, CMA dysfunction mediates aberrant ASYN toxicity, and may be a target for therapeutic intervention in PD and related disorders. Furthermore, macroautophagy induction in the context of ASYN over-expression, in contrast to other settings, appears to be a detrimental response, leading to neuronal death. 相似文献11.
Kelly J. Inglis David Chereau Elizabeth F. Brigham San-San Chiou Susanne Sch?bel Normand L. Frigon Mei Yu Russell J. Caccavello Seth Nelson Ruth Motter Sarah Wright David Chian Pamela Santiago Ferdie Soriano Carla Ramos Kyle Powell Jason M. Goldstein Michael Babcock Ted Yednock Frederique Bard Guriqbal S. Basi Hing Sham Tamie J. Chilcote Lisa McConlogue Irene Griswold-Prenner John P. Anderson 《The Journal of biological chemistry》2009,284(5):2598-2602
Several neurological diseases, including Parkinson disease and dementia
with Lewy bodies, are characterized by the accumulation of α-synuclein
phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for
this phosphorylation have been the subject of intense investigation. Here we
submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible
kinase or SNK) is a principle contributor to α-synuclein phosphorylation
at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at
Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases
inhibited α-synuclein phosphorylation both in primary cortical cell
cultures and in mouse brain in vivo. Finally, specific knockdown of
PLK2 expression by transduction with short hairpin RNA constructs or by
knock-out of the plk2 gene reduced p-Ser-129 levels. These results
indicate that PLK2 plays a critical role in α-synuclein phosphorylation
in central nervous system.The importance of α-synuclein to the pathogenesis of Parkinson
disease (PD)4 and the
related disorder, dementia with Lewy bodies (DLB), is suggested by its
association with Lewy bodies and Lewy neurites, the inclusions that
characterize these diseases
(1–3),
and demonstrated by the existence of mutations that cause syndromes mimicking
sporadic PD and DLB
(4–6).
Furthermore, three separate mutations cause early onset forms of PD and DLB.
It is particularly telling that duplications or triplications of the gene
(7–9),
which increase levels of α-synuclein with no alteration in sequence,
also cause PD or DLB.α-Synuclein has been reported to be phosphorylated on serine
residues, at Ser-87 and Ser-129
(10), although to date only
the Ser-129 phosphorylation has been identified in the central nervous system
(11,
12). Phosphorylation at
tyrosine residues has been observed by some investigators
(13,
14) but not by others
(10–12).
Phosphorylation at Ser-129 (p-Ser-129) is of particular interest because the
majority of synuclein in Lewy bodies contains this modification
(15). In addition, p-Ser-129
was found to be the most extensive and consistent modification in a survey of
synuclein in Lewy bodies (11).
Results have been mixed from studies investigating the function of
phosphorylation using S129A and S129D mutations to respectively block and
mimic the modification. Although the phosphorylation mimic was associated with
pathology in studies in Drosophila
(16) and in transgenic mouse
models (17,
18), studies using
adeno-associated virus vectors to overexpress α-synuclein in rat
substantia nigra found an exacerbation of pathology with the S129A mutation,
whereas the S129D mutation was benign, if not protective
(19). Interpretation of these
studies is complicated by a recent study showing that the S129D and S129A
mutations themselves have effects on the aggregation properties of
α-synuclein independent of their effects on phosphorylation, with the
S129A mutation stimulating fibril formation
(20). Clearly, determination
of the role of p-Ser-129 phosphorylation would be helped by identification of
the responsible kinase. In addition, identification will provide a
pathologically relevant way to increase phosphorylation in a cell or animal
model.Several kinases have been proposed to phosphorylate α-synuclein,
including casein kinases 1 and 2
(10,
12,
21) and members of the
G-protein-coupled receptor kinase family
(22). In this report, we offer
evidence that a member of the polo-like kinase (PLK) family, PLK2 (or
serum-inducible kinase, SNK), functions as an α-synuclein kinase. The
ability of PLK2 to directly phosphorylate α-synuclein at Ser-129 is
established by overexpression in cell culture and by in vitro
reaction with the purified kinase. We show that PLK2 phosphorylates
α-synuclein in cells, including primary neuronal cultures, using a
series of kinase inhibitors as well as inhibition of expression with RNA
interference. In addition, inhibitor and knock-out studies in mouse brain
support a role for PLK2 as an α-synuclein kinase in vivo. 相似文献
12.
The present study determined whether putative phosphorylation sites within the M3/M4 cytoplasmic domain of the human 4 subunit of 42 neuronal nicotinic receptors are substrates for cAMP-dependent protein kinase (PKA) or protein kinase C (PKC). Five peptides corresponding to predicted phosphorylation sequences were synthesized, and phosphorylation was compared with standard peptide substrates for each kinase, that is, Kemptide for PKA and glycogen synthase (GS) 1-8 for PKC. VRCRSRSI had the highest affinity for PKA, with a Km of 44.5 M; Kemptide had a Km of 7.7 M. LMKRPSVVK and KARSLSVQH were also phosphorylated by PKA, but had lower affinities of 593 M and 2896 M, respectively. LMKRPSVVK had the highest affinity for PKC with a Km of 182 M; GS 1–8 had a Km of 2.1 M. VRCRSRSI had a comparative affinity for PKC with a Km of 327 M. PCKCTCKK was not phosphorylated by PKA, but was a substrate for PKC with a Km of 1392 M, whereas PGPSCKSP was not phosphorylated by either kinase. Based on these findings, results suggest that Ser-362 and Ser-486 on the human 4 subunit may be phosphorylated by either PKA or PKC, Ser-467 is a putative PKA site, and Thr-532 represents a likely PKC substrate; Ser-421 does not appear to be phosphorylated by either kinase. 相似文献
13.
Iria Carballo-Carbajal Susanne Weber-Endress Giorgio Rovelli Diane Chan Benjamin Wolozin Christian L. Klein Nadja Patenge Thomas Gasser Philipp J. Kahle 《Cellular signalling》2010,22(5):821-827
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of autosomal-dominant Parkinson's disease (PD). The second known autosomal-dominant PD gene (SNCA) encodes α-synuclein, which is deposited in Lewy bodies, the neuropathological hallmark of PD. LRRK2 contains a kinase domain with homology to mitogen-activated protein kinase kinase kinases (MAPKKKs) and its activity has been suggested to be a key factor in LRRK2-associated PD. Here we investigated the role of LRRK2 in signal transduction pathways to identify putative PD-relevant downstream targets. Over-expression of wild-type [wt]LRRK2 in human embryonic kidney HEK293 cells selectively activated the extracellular signal-regulated kinase (ERK) module. PD-associated mutants G2019S and R1441C, but not kinase-dead LRRK2, induced ERK phosphorylation to the same extent as [wt]LRRK2, indicating that this effect is kinase-dependent. However, ERK activation by mutant R1441C and G2019S was significantly slower than that for [wt]LRRK2, despite similar levels of expression. Furthermore, induction of the ERK module by LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126. This pathway linking the two dominant PD genes LRRK2 and SNCA may offer an interesting target for drug therapy in both familial and sporadic disease. 相似文献
14.
Nadejda L. Korneeva Anren Song Hermann Gram Mary Ann Edens Robert E. Rhoads 《The Journal of biological chemistry》2016,291(7):3455-3467
The MAPK-interacting kinases 1 and 2 (MNK1 and MNK2) are activated by extracellular signal-regulated kinases 1 and 2 (ERK1/2) or p38 in response to cellular stress and extracellular stimuli that include growth factors, cytokines, and hormones. Modulation of MNK activity affects translation of mRNAs involved in the cell cycle, cancer progression, and cell survival. However, the mechanism by which MNK selectively affects translation of these mRNAs is not understood. MNK binds eukaryotic translation initiation factor 4G (eIF4G) and phosphorylates the cap-binding protein eIF4E. Using a cell-free translation system from rabbit reticulocytes programmed with mRNAs containing different 5′-ends, we show that an MNK inhibitor, , affects translation of only those mRNAs that contain both a cap and a hairpin in the 5′-UTR. Similarly, a C-terminal fragment of human eIF4G-1, eIF4G(1357–1600), which prevents binding of MNK to intact eIF4G, reduces eIF4E phosphorylation and inhibits translation of only capped and hairpin-containing mRNAs. Analysis of proteins bound to m7GTP-Sepharose reveals that both CGP and eIF4G(1357–1600) decrease binding of eIF4E to eIF4G. These data suggest that MNK stimulates translation only of mRNAs containing both a cap and 5′-terminal RNA duplex via eIF4E phosphorylation, thereby enhancing the coupled cap-binding and RNA-unwinding activities of eIF4F. CGP57380相似文献
15.
Elisa Basso Pedro Antas Zrinka Marijanovic Susana Gonçalves Sandra Tenreiro Tiago Fleming Outeiro 《Molecular neurobiology》2013,48(3):854-862
Phosphorylation of α-synuclein (aSyn) on serine 129 is one of the major post-translation modifications found in Lewy bodies, the typical pathological hallmark of Parkinson’s disease. Here, we found that both PLK2 and PLK3 phosphorylate aSyn on serine 129 in yeast. However, only PLK2 increased aSyn cytotoxicity and the percentage of cells presenting cytoplasmic foci. Consistently, in mammalian cells, PLK2 induced aSyn phosphorylation on serine 129 and induced an increase in the size of the inclusions. Our study supports a role for PLK2 in the generation of aSyn inclusions by a mechanism that does not depend directly on serine 129 phosphorylation. 相似文献
16.
Maria Eugenia Herva Shahin Zibaee Graham Fraser Roger A. Barker Michel Goedert Maria Grazia Spillantini 《The Journal of biological chemistry》2014,289(17):11897-11905
Filaments made of α-synuclein form the characteristic Lewy pathology in Parkinson and other diseases. The formation of α-synuclein filaments can be reproduced in vitro by incubation of recombinant protein, but the filament growth is very slow and highly variable and so unsuitable for fast high throughput anti-aggregation drug screening. To overcome this obstacle we have investigated whether the protein misfolding cyclic amplification (PMCA) technique, used for fast amplification of prion protein aggregates, could be adapted for growing α-synuclein aggregates and thus suitable for screening of drugs to affect α-synuclein aggregation for the treatment of the yet incurable α-synucleinopathies. Circular dichroism, electron microscopy, and native and SDS-polyacrylamide gels were used to demonstrate α-synuclein aggregate formation by PMCA, and the strain imprint of the α-synuclein fibrils was studied by proteinase K digestion. We also demonstrated that α-synuclein fibrils are able to seed new α-synuclein PMCA reactions and to enter and aggregate in cells in culture. In particular, we have generated a line of “chronically infected” cells, which transmit α-synuclein aggregates even after multiple passages. To evaluate the sensitivity of the PMCA system as an α-synuclein anti-aggregating drug screening assay a panel of 10 drugs was tested. Anti-amyloid compounds proved efficient in inhibiting α-synuclein fibril formation induced by PMCA. Our results show that α-synuclein PMCA is a fast and reproducible system that could be used as a high throughput screening method for finding new α-synuclein anti-aggregating compounds. 相似文献
17.
Simon M. L. Paine Glenn Anderson Karen Bedford Karen Lawler R. John Mayer James Lowe Lynn Bedford 《PloS one》2013,8(1)
Parkinson’s disease (PD) is characterized by the progressive degeneration of substantia nigra pars compacta (SNpc) dopaminergic neurones and the formation of Lewy bodies (LB) in a proportion of the remaining neurones. α-synuclein is the main component of LB, but the pathological mechanisms that lead to neurodegeneration associated with LB formation remain unclear. Three pivotal elements have emerged in the development of PD: α-synuclein, mitochondria and protein degradation systems. We previously reported a unique model, created by conditional genetic depletion of 26S proteasomes in the SNpc of mice, which mechanistically links these three elements with the neuropathology of PD: progressive neurodegeneration and intraneuronal inclusion formation. Using this model, we tested the hypothesis that α-synuclein was essential for the formation of inclusions and neurodegeneration caused by 26S proteasomal depletion. We found that both of these processes were independent of α-synuclein. This provides an important insight into the relationship between the proteasome, α-synuclein, inclusion formation and neurodegeneration. We also show that the autophagy-lysosomal pathway is not activated in 26S proteasome-depleted neurones. This leads us to suggest that the paranuclear accumulation of mitochondria in inclusions in our model may reflect a role for the ubiquitin proteasome system in mitochondrial homeostasis and that neurodegeneration may be mediated through mitochondrial factors linked to inclusion biogenesis. 相似文献
18.
Results of classical and structural bioinformatical research allow to predict casein kinase 2 dependent phosphorylation of conservative residues of Ser94 and Ser419 in Trypanosoma and Arabidopsis α-tubulin. Location of these residues in the region of internal contact of α-/β-tubulin heterodimer has been demonstrated. It is hypothesized that phosphorylation of Ser94 can affect dimerization of α-/β-tubulin in Trypanosoma and Arabidopsis. Most likely, potential phosphorylation of Ser419 does not have a direct effect on microtubule structure but is related to interaction with associated proteins, in particular with kinesins. 相似文献
19.
(p-Chlorophenoxy)isobutyric acid (PCIB) inhibited indole-3-acetic acid (IAA)-induced ethylene production in etiolated mung bean hypocotyl sections. The endogenous level of 1-aminocyclopropane-1-carboxylic acid (ACC) was not significantly affected by PCIB, indicating that PCIB exerted its effect primarily by inhibiting the activity of the ethylene-forming enzyme (EFE). This conclusion was supported by the observations that PCIB inhibited the conversion of exogenously applied ACC to ethylene. The inhibitory effect of PCIB was already evident with 0.05 mM PCIB, and it increased with time after application of the inhibitor. PCIB also significantly inhibited ethylene production in apple fruit tissues, but it only slightly reduced the level of endogenous ACC. Similar to mung bean, EFE activity in apple tissue was significantly inhibited by PCIB. The possibility that PCIB also inhibits auxin-induced ACC synthase activity is discussed. 相似文献
20.
《生物化学与生物物理学报:疾病的分子基础》2020,1866(10):165876
TAR DNA binding protein (TDP-43) is a DNA/RNA binding protein whose pathological role in amyotrophic lateral sclerosis (ALS) and frontal temporal lobe dementia (FTLD) via formation of protein aggregates is well established. In contrast, knowledge concerning its interactions with other neuropathological aggregating proteins is poorly understood. Human α-synuclein (HASN) elicits dopaminergic neuron degeneration via protein aggregation in Parkinson's disease. HASN protein aggregates are also found in TDP-43 lesions and colocalize in Lewy Body Dementia (LBD). To better understand the interactions of TDP-43 and HASN, we investigated the effects of genetic deletion of tdp-1, the Caenorhabditis elegans ortholog of human TDP-43, as well as overexpression of TDP-43, in transgenic models overexpressing HASNWT and HASNA53T. Tdp-1 deletion improved the posture, movement, and developmental delay observed in transgenic animals pan-neuronally overexpressing HASNA53T, and attenuated the loss and impairment of dopaminergic neurons caused by HASNA53T or HASNWT overexpression. Tdp-1 deletion also led to a decrease in protein level, mRNA level and aggregate formation of HASN in living animals. RNA-seq studies suggested that tdp-1 supports expression of lysosomal genes and decreases expression of genes involved in heat shock. RNAi demonstrated that heat shock proteins can mediate HASN neuropathology. Co-overexpression of both human TDP-43 and HASNWT resulted in locomotion deficits, shorter lifespan, and more severe dopaminergic neuron impairments compared to single transgenes. Our results suggest TDP-1/TDP-43 potentiates HASN mediated neurodegeneration in C. elegans. This study indicates a multifunctional role for TDP-1/TDP-43 in neurodegeneration involving HASN. 相似文献